Intravenous Immunoglobulin Replacement Therapy for Persistent COVID-19 in Patients With B-cell Impairment
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized controlled trial aiming to investigate the efficacy of
intravenous immunoglobulin (IVIG) replacement therapy under the hypothesis that
immunoglobulin replacement would have therapeutic effects on persistent COVID-19 in patients
with B-cell impairment.